Markets:

Overview

News

Currencies

International

Treasuries

ARS Pharmaceuticals, Inc. - Common Stock (NQ:SPRY)

8.875 -0.175 (-1.93%)

Streaming Delayed Price Updated: 3:56 PM EDT, Mar 10, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about ARS Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 Next >

Got $300? 2 Biotech Stocks to Buy and Hold Forever ↗

February 16, 2026

These two biotechs only have one marketable therapy each, but both have blockbuster potential.

Via The Motley Fool

ARS Pharma SPRY Q3 2025 Earnings Call Transcript ↗

November 10, 2025

ARS Pharma SPRY Q3 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

ARS Pharmaceuticals Inc (NASDAQ:SPRY) Tops Q3 2025 Revenue Forecasts Amid Wider-Than-Expected Loss ↗

November 10, 2025

ARS Pharma beats Q3 2025 revenue estimates with strong neffy sales. The company reports a wider loss but shows robust commercial growth and global expansion.

Via Chartmill

Earnings Scheduled For November 10, 2025 ↗

November 10, 2025

Via Benzinga

Earnings Outlook For ARS Pharmaceuticals ↗

November 07, 2025

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session ↗

October 03, 2025

Via Benzinga

Earnings Outlook For ARS Pharmaceuticals ↗

August 12, 2025

Via Benzinga

ARS Pharmaceuticals's Earnings: A Preview ↗

May 13, 2025

Via Benzinga

ARS Pharma Urges FDA To Delay Approval Of Aquestive's Allergic Reaction Treatment ↗

September 23, 2025

ARS Pharmaceuticals petitioned the FDA to delay approval of Aquestive's epinephrine film, citing safety, dosing, and cardiovascular concerns.

Via Benzinga

ARS Pharma Sales Jump 3,040% in Q2 ↗

August 13, 2025

Via The Motley Fool

ARS Pharmaceuticals Inc (NASDAQ:SPRY) Reports Mixed Q2 2025 Earnings with Revenue Beat but Investor Caution Persists ↗

August 13, 2025

ARS Pharma Q2 2025 results: $15.7M revenue beats estimates, but stock dips amid high SG&A costs. neffy gains traction with 93% U.S. coverage and global expansion underway.

Via Chartmill

Jim Cramer Is All Aboard Union Pacific, But Shows No Love For Orphan Drugs ↗

June 12, 2025

Jim Cramer recommends Union Pacific but is "getting tired of the orphan drug model." Here's what the "Mad Money" host said.

Via Benzinga

Earnings Scheduled For November 13, 2024 ↗

November 13, 2024

Via Benzinga

Insights Ahead: ARS Pharmaceuticals's Quarterly Earnings ↗

November 12, 2024

Via Benzinga

Where ARS Pharmaceuticals Stands With Analysts ↗

October 08, 2024

Via Benzinga

Analyst Ratings For ARS Pharmaceuticals ↗

September 09, 2024

Via Benzinga

Earnings Scheduled For August 13, 2025 ↗

August 13, 2025

Via Benzinga

Earnings Scheduled For May 14, 2025 ↗

May 14, 2025

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

March 20, 2025

Via Benzinga

Which stocks are gapping on Thursday? ↗

March 20, 2025

The market is filled with gapping stocks in Thursday's session. Let's discover which stocks are showing gap-ups and gap-downs.

Via Chartmill

ARS Pharma Retakes Its 50-Day Line In Bullish Post-Earnings Move. Here's Why. ↗

March 20, 2025

The company is known for its first-of-a-kind drug, a nasal treatment for emergency allergic reactions.

Via Investor's Business Daily

Jabil Posts Better-Than-Expected Earnings, Joins Darden Restaurants, QXO, Five Below And Other Big Stocks Moving Higher On Thursday ↗

March 20, 2025

Via Benzinga

Earnings Scheduled For March 20, 2025 ↗

March 20, 2025

Via Benzinga

FDA Approves ARS Pharmaceuticals' Lower Dose Neffy Nasal Spray For Emergency Allergy Treatment ↗

March 06, 2025

FDA approves ARS Pharma's Neffy 1 mg, the first nasal epinephrine spray for children with severe allergies, offering a needle-free alternative to autoinjectors.

Via Benzinga

Stock Market Rises On Tame Inflation, Bank Earnings: Weekly Review ↗

January 17, 2025

Many stocks flashed buy signals as the major indexes rose to or above key levels.

Via Investor's Business Daily

Topics Economy

BridgeBio, ARS Pharma, Harmony Bio Shine At JPM. But SpringWorks, Beam Take Their Lumps. ↗

January 13, 2025

Some companies saw their shares skyrocket on preliminary reports, but others took hits.

Via Investor's Business Daily

ARS Pharma Jumps After Inking $145 Million Deal For Epinephrine Nasal Spray ↗

November 11, 2024

Epinephrine is usually delivered in an auto-injector. This company is the first to win approval for a nasal spray version of it.

Via Investor's Business Daily

ARS Pharmaceuticals Inks Licensing Pact For Neffy Allergic Reaction Treatment, Analyst Sees Further Stock Upside Despite 200% Surge In 2024 ↗

November 11, 2024

ALK and ARS Pharmaceuticals sign a deal giving ALK global rights to Neffy nasal spray outside key regions, targeting peak sales of around $400 million in anaphylaxis treatment.

Via Benzinga

Newly Approved ARS Pharmaceuticals' Needle-Free Neffy Offers Convenience Over EpiPen For Allergic Reaction, But Real-World Efficacy Questioned ↗

August 23, 2024

Neffy, a nasal spray alternative to EpiPen, offers convenience and longer shelf life but faces skepticism from allergists due to limited real-world testing and potential insurance hurdles.

Via Benzinga

ARS Pharmaceuticals 'Neffy Uniquely Positioned With Potential To Change Allergy Treatment Paradigm For First Time In 40 years:' Analyst ↗

August 20, 2024

"FDA recently approved ARS Pharmaceuticals' neffy nasal spray for emergency allergic reactions, offering an alternative to epinephrine autoinjectors like EpiPen. Cantor sees strong market potential and...

Via Benzinga

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.